Newsletter

To help you fast-track CNS drug discovery while optimizing your R&D budget, ETAP-Lab is launching a series time-limited screening campaigns. These exclusive opportunities give you access to our robust neuron-based assays at discounted rates, with guaranteed turnaround times and expert scientific support. Three campaigns, three opportunities:January, February & March 2026 (with limited slots  per month) Ready to start a new project with us? Discover our attractive prices!     #1 PROTEINOPATHY PACK  Our Proteinopathy Pack is designed to assess compound

ETAP-LAB’s team will attend the upcoming NEUROSCIENCE 2025 from November 15 to 19, in San Diego (USA), with the presentation of 2 research posters. And for the first time, we will be exhibiting to welcome you & showcase our preclinical services in the neurovascular and neurological fields. We look forward to seeing you at this World’s Largest Neuroscience Conference, organized by the Society For Neuroscience (SFN), and with a qualitative programming for the scientists coming from around the planet!   📅 When to

ETAP-LAB, Preclinical CRO, pitching at the TECNIPLAST Scientific Symposium France 2025 next week! We’re pleased to announce that Sandra Robelet, Business Developer at ETAP-LAB, will be speaking at the TECNIPLAST Symposium, taking place in October 13–15, 2025 in Italy. 📌 When: October 14 🧠Topic: “The Complementarity of NAMs & Animal Models for translational AD's Drug Development”. We'll pitch about: ✔️ Challenges & Opportunities of Alternative Methods (NAMs) at preclinical stage ✔️ The "Brain-on-chip" alternative method (BIO-DIAMOND project*) in drug development stages, and how it can accelerate

Results of the strategic collaboration between ETAP-Lab and Revvity announced We are proud to announce that ETAP-Lab, preclinical CRO expert in neuroscience, partnered with Revvity, leader in High Content Screening (HCS) solutions, to push the boundaries of discovery by combining their expertise and technology.   Revvity has just launched the staining kit for astrocyte differentiation - tested and approved by ETAP-LAB - specially designed for iPSC-derived neuronal models.   At ETAP-LAB, our teams contributed to this successful launch thanks to: our neuroscience expertise,

Discover the excellent results on ischemic skin wounds in our Poster: "Pro-healing effects of Plasana One®, an argon-generated cold plasma on ischemic skin wounds”. Presented by Jean-François Bisson at the European Society for Dermatological Research (ESDR 2025, Antwerp, Belgium), featuring results from a client study on our ischemic skin wound model, conducted in collaboration with École Polytechnique, Laboratoire de Physique des Plasmas & Plasana Médical.   💡This study contributed to the preclinical development of the Plasana One® technology, an innovative device which is

By

Publication: Functional discrimination of CSF from Alzheimer’s patients in a brain on chip platform. Sci Rep 15, 29738 (2025). Authors: Miny, L., Rontard, J., Allouche, A. et al. Affiliated: NETRI (Lyon, France) Hospices Civils de Lyon – Department of Biochemistry and Molecular Biology, Neurodegenerative Pathologies (Bron, France) Lyon Neurosciences Research Center (CNRS UMR 5292 / INSERM U1028) ETAP-Lab – Preclinical Efficacy CRO (Vandoeuvre-Lès-Nancy, France) Abstract: Neurodegenerative diseases, including Alzheimer’s disease (AD), present significant diagnostic challenges due to overlapping symptoms and the invasive, time-consuming, and costly nature

By

Join us in Antwerp from September 10 to 13, 2025, for the annual congress of the European Society for Dermatological Research (ESDR). ETAP-Lab will be showcasing its expertise in preclinical dermatology through a dedicated booth (Booth #2) and a scientific poster session. 🔗 Learn more about the ESDR Meeting   Meet Our Team at Booth #2 Our team will be pleased to present our offer of preclinical dermatological models in skin inflammation, wound healing as well as skin grafting. Schedule a meeting now with Jean-François

Consult the publication in which ETAP-LAB was mentioned and acknowledged for our in vitro hippocampal neuron model—challenged with own-manufactured Tau oligomers: "A novel allosteric GCase modulator prevents Tau accumulation in GBA1WT and GBA1L444P/L444P cellular models. Sci Rep 15, 17646 (2025)." Published 21 May 2025 - Ciccaldo, M., Pérez-Carmona, N., Piovesana, E. et al. https://www.nature.com/articles/s41598-025-02346-8 Authors: Matteo Ciccaldo1, Natàlia Pérez-Carmona2, Ester Piovesana1, Sara Cano-Crespo2, Ana Ruano2, Aida Delgado2, Ilaria Fregno3, Beatriz Calvo-Flores Guzmán4, Manolo Bellotto4, Maurizio Molinari3,5, Joanne Taylor6, Stéphanie Papin1, Ana María

By

Dr Jean-François BISSON, PhD, and Lianna RAZAFITRIMO, presented the team’s research during the SPIN 2025 (Congress of the Skin Inflammation & Psoriasis International Network)  in the poster: "Behavioural assessment as a tool for evaluation of efficacy therapies associated with well-being recovery in preclinical models of skin diseases".   Learn more about our preclinical services in Dermatology in the poster! Until the poster is available here, don’t wait any longer and ask for the poster in PDF!   [mkdf_button size="" type="" text="EASY REQUEST OF POSTER" custom_class="" icon_pack="font_awesome" fa_icon=""

By